天美传媒

Abstract

Modern oncology is marked by rapid advancements in personalized treatment and diagnostic strategies. Immunotherapies, including immune checkpoint inhibitors and CAR T-cell therapies, show significant promise, though overcoming resistance mechanisms remains a challenge [1, 3, 5, 9, 10]. Precision approaches leverage liquid biopsies and circulating tumor DNA for real-time monitoring and early detection [4, 7], alongside targeting DNA damage response pathways [2]. The integration of multi-omics data and Artificial Intelligence is poised to further enhance diagnostic accuracy, personalize therapies, and accelerate drug discovery, driving a future of more effective cancer management [6, 8].